A
Alina N. Egorova
Publications - 7
Citations - 249
Alina N. Egorova is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 4 publications receiving 117 citations.
Papers
More filters
Journal ArticleDOI
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.
Andrey Alexandrovich Ivashchenko,Kirill A. Dmitriev,Natalia V. Vostokova,Valeria N Azarova,Andrew A. Blinow,Alina N. Egorova,Ivan G. Gordeev,Alexey P. Ilin,Ruben N. Karapetian,Dmitry V. Kravchenko,Nikita V. Lomakin,Elena A. Merkulova,Natalia A. Papazova,Elena P. Pavlikova,Nikolay Filippovich Savchuk,Elena N Simakina,Tagir A. Sitdekov,Elena A Smolyarchuk,Elena G. Tikhomolova,Elena V Yakubova,Alexandre V. Ivachtchenko +20 more
TL;DR: In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.
Posted ContentDOI
AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
Andrey Alexandrovich Ivashchenko,Kirill A. Dmitriev,Natalia V. Vostokova,Valeria N Azarova,Andrew A. Blinow,Alina N. Egorova,Ivan G. Gordeev,Alexey P. Ilin,Ruben N. Karapetian,Dmitry V. Kravchenko,Nikita V. Lomakin,Elena A. Merkulova,Natalia A. Papazova,Elena P. Pavlikova,Nikolay Filippovich Savchuk,Elena N Simakina,Tagir A. Sitdekov,Elena A Smolyarchuk,Elena G. Tikhomolova,Elena V Yakubova,Alexandre V. Ivachtchenko +20 more
TL;DR: In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients.
Journal ArticleDOI
Effect of Aprotinin and Avifavir ® Combination Therapy for Moderate COVID-19 Patients.
Andrey Alexandrovich Ivashchenko,Valeria N Azarova,Alina N. Egorova,Ruben N. Karapetian,Dmitry V. Kravchenko,Natalia V Krivonos,Vladimir G Loginov,Stanislav V Poyarkov,Elena A. Merkulova,Olga S Rosinkova,Nikolay Filippovich Savchuk,Mikhail A Topr,Elena N Simakina,Elena V Yakubova,Alexandre V. Ivachtchenko +14 more
TL;DR: In this paper, the authors studied the efficacy of Aprotinin (nonspecific serine proteases inhibitor) in combination with Avifavir® or Hydroxychloroquine (HCQ) drugs, which are recommended by the Russian Ministry of Health for the treatment therapy of moderate COVID-19 patients.
Journal ArticleDOI
Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results.
Valentina Myachikova,Alexey Maslyanskiy,Olga Moiseeva,E. Gleykina,Yan Lavrovsky,Antonio L'Abbate,S. A. Grishin,Alina N. Egorova,M. Samsonov +8 more
TL;DR: Goflikicept as discussed by the authors is a new IL-1 inhibitor for patients with recurrent pericarditis (IRP), which is a rare auto-inflammatory disease, and has been shown to reduce the risk of recurrence compared with placebo.
Journal ArticleDOI
Pos1071 the impact of comorbidities on the efficacy of il-6 inhibitor olokizumab compared to adalimumab
E. T. Feist,Michael E. Luggen,E N Nasonov,Sergey Yakushin,D. Bukhanova,Alina N. Egorova,S. A. Grishin,Maria Samsonov,Josef S Smolen +8 more
TL;DR: In this paper , the authors evaluated the impact of comorbidity burden on the efficacy of IL-6 inhibitor olokizumab and TNF-α inhibitor adalimumab (ADA) in the CREDO-2 clinical trial cohort of patients with active rheumatoid arthritis (RA).